Data from Novo Nordisk’s A1chieve study shows Type 2 diabetes patients can improve their blood glucose control with a low occurrence of low blood sugar (hypoglycemia).

Before treatment with a Novo Nordisk insulin analogue was initiated, the average blood glucose control (HbA1c) among the 66,726 study participants was 9.5%, which is above the internationally recognized target of 7%.

After 24 weeks of treatment with a Novo Nordisk insulin analogue there was a significant reduction in HbA1c levels of 2.1%, from 9.5% to 7.4%. Reported rates of overall hypoglycemia slightly increased in those new to insulin and fell in those who switched from other insulin therapies.

Before entering into the study, people were started on one of three Novo Nordisk insulin analogue regimens based on their physician’s clinical judgment. The primary aim of the study was to evaluate the clinical safety of the study insulin’s in routine clinical practice, assessed by the incidence of serious adverse drug reactions (SADRs) including rates of major hypoglycemia.

After 24 weeks, clinically meaningful improvements in overall blood glucose control were found with all three insulin analogue regimens: For people taking premix insulin NovoMix 30, HbA1c decreased from 9.5% to 7.3% for insulin-naive and from 9.4% to 7.5% for prior insulin users. In people taking the long-acting insulin Levemir, HbA1c decreased from 9.5% to 7.4% for insulin-naive and from 9.3% to 7.6 % for prior insulin users. For people taking the fast-acting meal-time insulin NovoRapid in combination with a basal insulin, HbA1c decreased from 10.1% to 7.3% for insulin-naive and from 9.4% to 7.5% for prior insulin users.

 “Improvements in HbA1c of this magnitude are of significant clinical importance. We know that every 1.0% reduction in HbA1c is associated with reducing the risk of long-term diabetes complications. Seeing improvements such as those we have seen in the study potentially mean a better longer term outlook for the people with diabetes involved,” says Philip Home, professor of Diabetes Medicine at Newcastle University, England.

The research was published in Diabetes Research and Clinical Practice.

Release Date: Dec. 5, 2011
Source: Novo Nordisk